These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 30198840

  • 1. Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data.
    Uchida J, Iwai T, Nishide S, Kabei K, Kuwabara N, Naganuma T, Kumada N, Takemoto Y, Nakatani T.
    Exp Clin Transplant; 2019 Apr; 17(2):190-195. PubMed ID: 30198840
    [Abstract] [Full Text] [Related]

  • 2. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 3. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 4. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A, Iwai T, Uchida J.
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [Abstract] [Full Text] [Related]

  • 5. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients.
    Sharif A, Alachkar N, Bagnasco S, Geetha D, Gupta G, Womer K, Arend L, Racusen L, Montgomery R, Kraus E.
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1320-7. PubMed ID: 22626962
    [Abstract] [Full Text] [Related]

  • 6. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, Watarai Y, Yoshimura N, Tanabe K, Morozumi K, Shimazu M, IDEC-C2B8 ABO-I KTx Study Group.
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [Abstract] [Full Text] [Related]

  • 7. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S, Hwang E, Park S, Park U, Kim H, Cho W.
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [Abstract] [Full Text] [Related]

  • 9. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
    Nanmoku K, Shinzato T, Kubo T, Shimizu T, Kimura T, Yagisawa T.
    Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
    [Abstract] [Full Text] [Related]

  • 10. Outcomes of Pediatric ABO-incompatible Living Kidney Transplantations From 2002 to 2015: An Analysis of the Japanese Kidney Transplant Registry.
    Hattori M, Mieno M, Shishido S, Aikawa A, Ushigome H, Ohshima S, Takahashi K, Hasegawa A, Japan Society for Transplantation and Japanese Society for Clinical Renal Transplantation.
    Transplantation; 2018 Nov; 102(11):1934-1942. PubMed ID: 29781948
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y, Aikawa A, Itabashi Y, Muramatsu M, Hyoudou Y, Shinoda K, Takahashi Y, Sakurabayashi K, Mizutani T, Oguchi H, Kawamura T, Sakai K, Shishido S.
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [Abstract] [Full Text] [Related]

  • 12. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
    Ashimine S, Watarai Y, Yamamoto T, Hiramitsu T, Tsujita M, Nanmoku K, Goto N, Takeda A, Katayama A, Uchida K, Kobayashi T.
    Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
    [Abstract] [Full Text] [Related]

  • 13. Immune Desensitization Allows Pediatric Blood Group Incompatible Kidney Transplantation.
    Stojanovic J, Adamusiak A, Kessaris N, Chandak P, Ahmed Z, Sebire NJ, Walsh G, Jones HE, Marks SD, Mamode N.
    Transplantation; 2017 Jun; 101(6):1242-1246. PubMed ID: 27463537
    [Abstract] [Full Text] [Related]

  • 14. Conversion From Steroid to Everolimus in Maintenance Kidney Transplant Recipients With Posttransplant Diabetes Mellitus.
    Nanmoku K, Kurosawa A, Kubo T, Shinzato T, Shimizu T, Kimura T, Yagisawa T.
    Exp Clin Transplant; 2019 Feb; 17(1):47-51. PubMed ID: 29911959
    [Abstract] [Full Text] [Related]

  • 15. Incidence and Outcome of C4d Staining With Tubulointerstitial Inflammation in Blood Group-incompatible Kidney Transplantation.
    Couzi L, Perera R, Manook M, Barnett AN, Shaw O, Kessaris N, Marks SD, Dorling A, Mamode N.
    Transplantation; 2015 Jul; 99(7):1487-94. PubMed ID: 26151608
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 17. Beyond C4d: the ultrastructural appearances of endothelium in ABO-incompatible renal allografts.
    Bröcker V, Pfaffenbach A, Habicht A, Chatzikyrkou C, Kreipe HH, Haller H, Scheffner I, Gwinner W, Zilian E, Immenschuh S, Schwarz A, Horn PA, Heinemann FM, Becker JU.
    Nephrol Dial Transplant; 2013 Dec; 28(12):3101-9. PubMed ID: 24081856
    [Abstract] [Full Text] [Related]

  • 18. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K, Uchida J, Iwai T, Yamasaki T, Kuwabara N, Naganuma T, Kumada N, Nakatani T.
    Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
    [Abstract] [Full Text] [Related]

  • 19. ABO incompatible kidney transplantation: the Saudi experience.
    Ali T, Broering D, Aleid H, Brockmann J, Alhumaidan H, Hammad E, Shah Y, Elgamal H, Alahmadi I, Hussein M, Raza S, Alabassi A, Ibrahim I, Shoukri M, Almeshari K.
    Saudi J Kidney Dis Transpl; 2019 Aug; 30(3):655-662. PubMed ID: 31249230
    [Abstract] [Full Text] [Related]

  • 20. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE, Siebert D, Süsal C, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C.
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.